遵循COMPASS方案:症状性外周动脉疾病患者血运重建后抗血栓处方趋势
本研究观察本机构症状性外周动脉疾病患者血运重建后COMPASS剂量抗血栓处方的应用趋势。结果显示COMPASS处方率持续偏低,与抗血小板单药治疗相当(33.4% vs 34.6%),腔内治疗后者显著低于外科旁路(28.8% vs 59.3%)。作者认为约三分之一患者接受抗血小板单药治疗属于治疗不足,存在医疗优化空间。
要点
- COMPASS剂量处方率与抗血小板单药治疗相当(33.4% vs 34.6%)。
- 腔内治疗后COMPASS处方率显著低于外科旁路(28.8% vs 59.3%)。
- 慢性肢体威胁性缺血患者COMPASS处方率低(29.8%)。
核心结论
- 本观察性研究中,三分之一患者接受抗血小板单药治疗属于治疗不足,存在显著医疗优化空间。
- 腔内治疗患者及慢性肢体威胁性缺血高危亚组尤其明显。
- 作者强调对符合COMPASS剂量条件的患者,双通路抗血栓治疗对优化当前最佳证据药物治疗的重要性。
研究设计与样本
- 观察性研究,纳入本机构有记录的下肢动脉粥样硬化性外周动脉疾病且符合COMPASS剂量条件的患者。
- 血运重建策略包括腔内治疗(n=299)、腹股沟上旁路(n=18)和腹股沟下旁路(n=36)。
主要发现
- 腔内与外科策略复合的COMPASS处方率随时间持续偏低,无增加趋势。
- COMPASS剂量处方率与抗血小板单药治疗相当(33.4% vs 34.6%)。
- 腔内治疗后COMPASS处方率显著低于外科旁路(28.8% vs 59.3%)。
- 外科旁路后COMPASS处方趋势较好:腹股沟上旁路患者50.0%、腹股沟下旁路患者63.9%出院时接受COMPASS。
- 慢性肢体威胁性缺血患者COMPASS处方率低(29.8%),且无增加趋势;观察期内再干预患者中从阿司匹林单药转换为COMPASS的比率低(3/26,11.5%)。
临床怎么用
- 作者认为对符合COMPASS剂量条件的患者,应重视双通路抗血栓治疗以优化当前最佳证据药物治疗。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Vascular Outcomes Study of aspirin (ASA) Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for peripheral artery disease (PAD) trial demonstrated the superiority of ASA and low-dose rivaroxaban (Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial dosing) compared with ASA alone in reducing major adverse cardiovascular events and major adverse limb events. We studied the COMPASS discharge prescription patterns in patients with symptomatic PAD who have undergone revascularization in our institution, since the time of publication of the Vascular Outcomes Study of ASA Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD trial. METHODS: All patients included in this study had documented lower-extremity atherosclerotic PAD and were eligible for COMPASS dosing. Revascularization strategies included endovascular (n = 299), suprainguinal bypass (n = 18), and infrainguinal bypass (n = 36). RESULTS: COMPASS prescription patterns for the composite of endovascular and surgical strategies demonstrated a consistently low rate over time, without a trend toward increasing use. COMPASS dosing was prescribed as often as antiplatelet monotherapy (33.4% COMPASS vs. 34.6% antiplatelet monotherapy). This low COMPASS prescription rate was driven by significantly lower COMPASS prescriptions following endovascular therapy compared to surgical bypass (28.8% endovascular vs. 59.3% surgical bypass). COMPASS prescriptions following surgical bypass showed better trends; half of suprainguinal bypass patients (50.0%) and two-thirds of infrainguinal bypass patients (63.9%) were discharged on COMPASS. Despite patients with chronic limb-threatening ischemia (CLTI) representing a high-risk limb presentation, COMPASS prescriptions were low (29.8%), as opposed to patients without CLTI, and did not show a trend toward increasing use. In patients who underwent reinterventions throughout the observation period, there was a low conversion rate from ASA alone to COMPASS (3/26, 11.5%). CONCLUSIONS: In this observational study, one-third of patients were undertreated by prescription of antiplatelet monotherapy, indicating that there is significant room for medical optimization. This is especially true of patients undergoing endovascular treatment, including the high-risk subgroup of patients with CLTI. We highlight the importance of dual pathway antithrombotic therapy in patients eligible for COMPASS dosing to optimize best current evidence medical therapy.
引用
- Elzawy G, Chan J, Eisenberg N, et al. Following the COMPASS: Antithrombotic Prescription Trends in Patients with Symptomatic Peripheral Arterial Disease following Revascularization. Ann Vasc Surg. 2024. PMID: 38851315. doi:10.1016/j.avsg.2024.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。